Sep. 22 at 10:25 PM
$AUPH @hh16 (1/2)
Gonna answer you here so people can see the huge difference between the Hikma v. Amarin and our case. Yes they got a 9-0 skinny label verdict in favor of them but you can't correlate entirely different diseases and IP from one to another.
Teva's Concession Changes the Leverage: In August 2026, Teva Pharmaceuticals explicitly stipulated that Aurinia's U.S. Patent Nos. 10,286,036 and 11,622,991 are valid, enforceable, and would be infringed by a generic launch. Teva agreed to sit out of the market until December 2036.
Lets move onto the science part. The Nature of the Patents: The core patent at issue (the '036 patent) covers a highly specific eGFR pharmacodynamic dosing protocol used during clinical trials to protect kidney function while maximizing efficacy. This is unlike the standard "indication" patents in the Amarin case (where Hikma could just carve out the cardiovascular indication from its label), it is significantly harder to carve out a necessary,
